Peptides for Pain: New Avenues for Lasting Relief

Peptides, short chains of amino acids found naturally in the body and in animal venoms, are reshaping how researchers approach chronic pain. The therapeutic peptide market was valued at roughly $46 billion in 2024 and is expected to grow to nearly $69 billion by 2028, with pain management as one of its most active frontiers.¹ Unlike conventional painkillers that tend to act through a single receptor, many peptide-based approaches exploit the body’s own signaling systems or borrow molecular tools from venomous creatures to block pain at its source. The result is a rapidly expanding toolkit that may eventually offer strong pain relief with fewer of the side effects that have made opioid drugs so dangerous.

How Your Body Already Fights Pain With Peptides

Your nervous system has a built-in pain-dampening circuit, and endogenous opioid peptides are central to it. Enkephalins, endorphins, and dynorphins are all naturally occurring peptides that bind to opioid receptors on nerve cells. One of their key functions is modulating pain responses through a descending circuit that runs from the brain’s periaqueductal gray region down to the spinal cord, where it can dial down incoming pain signals before they ever reach conscious awareness.² Techniques like acupuncture, transcutaneous electrical nerve stimulation, and spinal cord stimulation appear to work, at least partly, by triggering the release of these endogenous opioids.³

The problem is that the body breaks down its own pain-fighting peptides very quickly. Enkephalins, for instance, are chewed up within seconds by two enzymes in the brain and spinal cord. That rapid degradation limits their usefulness as a foundation for drugs, but it has inspired an entire line of research focused on slowing the breakdown rather than flooding the system with synthetic opioids from outside.

Dual Enkephalinase Inhibitors

Rather than introducing a foreign opioid, dual enkephalinase inhibitors, or DENKIs, work by protecting the enkephalins your body already produces. They block both of the enzymes responsible for chewing up enkephalins, which extends the peptides’ lifespan and amplifies their natural painkilling effects.⁴ The appeal is that enkephalin levels rise only where and when pain signals trigger their release, so the system is self-regulating in a way that exogenous opioids are not.⁵

Animal studies and early clinical work suggest that DENKIs produce fewer side effects than conventional opioids, and some researchers have proposed they could serve as both a pain treatment and a potential therapy for opioid withdrawal, because they activate the same receptors in a more controlled, physiological manner.⁶ The concept is elegant: instead of importing a powerful synthetic molecule that overwhelms the receptor system, you give the body’s own molecules a longer window to do their job.

Ziconotide and the Cone Snail Legacy

The first peptide approved by the FDA specifically for pain came not from a laboratory but from a marine cone snail. Ziconotide, approved in 2004, is a synthetic copy of a toxin produced by Conus magus. It works by blocking N-type calcium channels on nerve endings in the spinal cord, which prevents the release of pain-signaling chemicals.⁷ By interrupting nerve transmission at that level, it can provide powerful pain relief for people with severe chronic pain who have not responded to other treatments.⁸

Ziconotide’s mechanism has nothing to do with opioid receptors, which means it carries no risk of respiratory depression or the addictive potential associated with morphine-type drugs. But it is far from a simple pill. The peptide must be delivered directly into the spinal fluid through an implanted pump, because it cannot cross the blood-brain barrier or survive digestion. And its therapeutic window is narrow. Early clinical use was plagued by side effects because doctors titrated the dose too quickly. At higher doses, patients experienced dizziness, nausea, confusion, visual disturbances, and abnormal gait.⁹ Slower titration schedules have improved tolerability, but ziconotide remains a last-resort option reserved for the most refractory cases.

Despite those limitations, ziconotide demonstrated something important: a peptide derived from an animal venom could become a real drug, and its success has fueled a wave of research into other venom-sourced peptides.

Spider Venom and Nav1.7 Blockers

If you could shut down a single sodium channel and eliminate pain without numbing everything else, you’d have an ideal painkiller. That is the promise behind Nav1.7, a voltage-gated sodium channel found primarily on pain-sensing neurons. People born with loss-of-function mutations in the gene encoding Nav1.7 feel virtually no pain, yet their other senses and motor function remain intact. That genetic observation has made Nav1.7 one of the most pursued drug targets in pain research.

Spider venoms are a rich source of peptides that interact with sodium channels, and researchers have been engineering these toxins to be more selective for Nav1.7 while leaving other sodium channel subtypes alone.¹⁰ One well-characterized example, a peptide called Pn3a isolated from a tarantula species, inhibits Nav1.7 with 40- to over 900-fold selectivity compared to other sodium channel subtypes.¹¹ That degree of selectivity matters because blocking closely related channels like Nav1.5, which is critical for heart rhythm, would be dangerous.

The challenge is translating selectivity in a lab dish into a working drug in a living person. Off-target effects remain a significant hurdle, and researchers are actively engineering modifications to improve both specificity and stability of these venom-derived peptides.¹² No spider-venom-derived Nav1.7 blocker has reached the market yet, but the pipeline continues to attract serious investment. Venom peptides that target other pain-relevant receptors, including the heat- and capsaicin-sensing TRPV1 channel, are also under investigation.¹³

CGRP and the Migraine Breakthrough

One of the most visible success stories for peptide-related pain therapy involves calcitonin gene-related peptide, or CGRP. This signaling molecule is released by sensory nerve fibers and contributes to neurogenic inflammation, the process where nerve activity itself promotes swelling and sensitivity in surrounding tissue. CGRP is upregulated in inflammatory and neuropathic pain states, and it plays a role in sensitizing both the initial pain-sensing neurons and the second-order neurons deeper in the spinal cord that relay pain signals to the brain.¹⁴

In migraine specifically, CGRP release from nerve endings around blood vessels in the brain triggers vasodilation and sensitizes surrounding nociceptors, fueling the cascade of pain and sensory sensitivity that defines a migraine attack.¹⁵ The monoclonal antibodies and small-molecule antagonists that block CGRP or its receptor, drugs like erenumab, fremanezumab, and rimegepant, have transformed migraine prevention and treatment for millions of people. While these antibodies are proteins rather than small peptides, the entire therapeutic class exists because researchers mapped the role of a specific peptide in the pain pathway and then designed molecules to block it. CGRP’s involvement in non-migraine pain, including joint inflammation and neuropathic conditions, is an area of ongoing study.

Substance P and Pain Sensitization

Substance P is another peptide deeply embedded in pain signaling. It belongs to the tachykinin family, and together with its receptor, the NK1 receptor, it plays a well-established role in transmitting pain signals from the body’s periphery into the spinal cord.¹⁶ Where CGRP amplifies and sensitizes, substance P is more directly involved in carrying the pain message itself.

Blocking the NK1 receptor looked extremely promising in the 1990s, and pharmaceutical companies invested heavily in NK1 antagonists as next-generation painkillers. The drugs worked well in animal models but repeatedly failed in human clinical trials for pain. One NK1 antagonist, aprepitant, did find a second life as an anti-nausea drug for chemotherapy patients, but the hoped-for pain indication never materialized. The disconnect between animal results and human outcomes remains one of the cautionary tales of peptide-based drug development. It is a reminder that targeting a single peptide pathway, even one unambiguously involved in pain transmission, does not guarantee a successful drug.

Multifunctional Peptides and Biased Agonists

Chronic pain, especially neuropathic pain from nerve damage, involves multiple overlapping signaling pathways. A drug that hits only one target may not provide adequate relief, or it may drive compensatory mechanisms that create new problems. This has motivated the design of multifunctional peptides: single molecules engineered to engage two or more targets simultaneously.

One approach creates peptides that activate both mu and delta opioid receptors while also blocking cholecystokinin (CCK) receptors, which normally counteract opioid pain relief. Compounds like RSA 504 and RSA 601 demonstrated exactly this combination in animal models of neuropathic pain, reducing sensitivity to both mechanical and heat stimuli without the typical side effects of conventional opioids.¹⁷ Another line of research built on biphalin, a bivalent peptide that activates both mu and delta receptors with a cleaner side-effect profile than morphine, and then modified it into a more metabolically stable form called MACE2 that showed efficacy in several chronic pain models.¹⁸

A related strategy is “biased agonism,” where a peptide activates the same receptor as morphine but preferentially triggers one downstream signaling cascade over another. The mu-opioid receptor can signal through G proteins, which produce pain relief, or through beta-arrestin, which is linked to respiratory depression and constipation. Biased agonist peptides like KGFF03 and KGFF09, which also antagonize neuropeptide FF receptors, showed reduced respiratory depression in mice compared to an unbiased opioid of similar potency.¹⁹ These are still preclinical results, and biased agonism has stumbled before in late-stage trials with small-molecule drugs. But the peptide format gives chemists more structural flexibility to fine-tune signaling bias than traditional small molecules typically allow.

Neurotensin and Opioid-Free Pain Relief

Not every peptide approach to pain involves opioid receptors at all. Neurotensin is a 13-amino-acid peptide that acts through two receptor subtypes, NTS1 and NTS2, and researchers have shown that activating neurotensin pathways can reduce both inflammatory and neuropathic pain. In one study, neurons in the lateral hypothalamus that produce neurotensin were stimulated using a technique called chemogenetics, and the resulting pain relief was blocked when a neurotensin receptor antagonist was administered, confirming that the effect depended specifically on neurotensin signaling rather than some off-target mechanism.²⁰

On the drug development side, researchers have created macrocyclic (ring-shaped) neurotensin analogs that are highly selective for NTS2, achieving roughly 30,000-fold selectivity over NTS1. These compounds produced potent opioid-independent pain relief in animal models and could potentially be used either on their own or alongside low-dose opioids to reduce opioid-related side effects.²¹ The idea of “opioid-sparing” therapy, where a non-opioid drug allows a much lower opioid dose to achieve the same relief, is increasingly popular among pain researchers as a pragmatic middle ground between all-opioid and opioid-free strategies.

GLP-1 Receptor Agonists and an Unexpected Pain Connection

GLP-1 receptor agonists like semaglutide and liraglutide are best known for treating diabetes and, more recently, obesity. But emerging evidence suggests they may also dampen neuropathic pain. The proposed mechanism is not metabolic: GLP-1 receptors are expressed on glial cells and neurons in the spinal cord, and activating them appears to reduce neuroinflammation and central sensitization, the process by which the nervous system amplifies pain signals over time.²² This is still early-stage research, and it is worth being skeptical of any single mechanism explanation for drugs as widely studied as GLP-1 agonists. But if the pain-related findings hold up in larger clinical studies, a drug class already prescribed to millions could find an entirely new application.

The Delivery Problem

The biggest practical barrier for peptide painkillers is getting them where they need to go. Peptides are fragile. They are broken down in the gut, cleared rapidly from the bloodstream, and often cannot cross the blood-brain barrier, the tightly sealed layer of cells that separates blood vessels from brain tissue. Ziconotide’s requirement for an implanted intrathecal pump illustrates how severe this limitation can be.

Researchers are attacking the delivery problem from multiple angles. One approach is backbone cyclization, where the peptide’s chain is bent into a ring shape by connecting its two ends with a chemical bridge. This makes the molecule more resistant to the enzymes that would normally chop it apart. In one study, cyclization of a conotoxin called RgIA, which targets a nicotinic acetylcholine receptor subtype relevant to pain, improved its stability in human serum without disrupting the peptide’s three-dimensional shape.²³ Similar cyclization strategies have been applied to opioid peptides, producing analogs that can be taken orally and produce long-lasting, peripherally restricted pain relief with reduced side effects.²⁴

For peptides that need to reach the brain, cell-penetrating peptides (CPPs) offer a shuttle service. These short amino acid sequences can cross cell membranes, and when attached to a therapeutic peptide, they can carry it across the blood-brain barrier. In one experiment, the natural opioid peptide endomorphin-1 was linked to a CPP called SynB3 using different chemical tethers, which improved its ability to cross into the brain.²⁵ A different strategy used angiopep-2, a peptide that hitches a ride on a transport receptor naturally present on blood-brain barrier cells, to ferry morphine and its metabolite M6G into the brain. The conjugate produced stronger and longer-lasting pain relief than equivalent doses of unconjugated morphine or M6G.²⁶ If these shuttle strategies prove safe and scalable, they could eventually make intrathecal pumps unnecessary for some peptide drugs.

Immune Cells as Peripheral Pain Relievers

Pain does not only get managed in the brain and spinal cord. At sites of inflammation, immune cells that migrate to injured tissue carry their own supply of opioid peptides. When these cells arrive, they release enkephalins, endorphins, and dynorphins that bind to opioid receptors on nearby sensory nerve endings, producing measurable pain relief right at the source of the problem.²⁷ This peripheral opioid mechanism has been demonstrated in both animal models and human surgical settings.²⁸

The therapeutic implication is straightforward: if you can design peptides that activate peripheral opioid receptors without crossing into the central nervous system, you could potentially treat inflammatory pain without causing sedation, respiratory depression, or the euphoria that drives addiction. Some of the cyclic peptide designs mentioned earlier deliberately exploit this principle, producing compounds that stay in the periphery and act only where inflammation has upregulated opioid receptor expression. The concept is still largely preclinical, but it represents one of the cleaner paths toward separating pain relief from opioid side effects.

The Safety Question

A persistent hope in the peptide field is that peptide-based analgesics will be inherently safer than traditional opioids. The reasoning has several threads: peptides can be designed to stay outside the brain, they can exploit the body’s own regulatory mechanisms (as with DENKIs), and they can be engineered for biased signaling that avoids the pathways linked to dependence and respiratory depression. Overall, opioid peptides have been recognized as promising candidates for developing safer analgesics, and strategies like multifunctional design, biased agonism, and peripheral restriction have all shown reduced side effects in animal models.²⁹

But “safer in mice” is a familiar refrain in drug development, and the history of pain therapeutics is littered with molecules that looked cleaner in animal studies than they turned out to be in people. Ziconotide’s rocky early clinical experience is one example: the drug is genuinely non-addictive and does not suppress breathing, but its neurological side effects required careful management that took years to optimize.⁹ Another cone snail-derived peptide, Xen2174, which works by blocking norepinephrine reuptake in the spinal cord, was tested via intrathecal injection in a clinical trial. The most common adverse event was post-lumbar-puncture syndrome, and the highest dose group exceeded a predefined safety margin based on cerebrospinal fluid drug levels, underscoring how tricky dosing can be for intrathecally delivered peptides.³⁰

Living With an Intrathecal Pump

For the small number of patients currently receiving peptide-based pain therapy, the experience is defined by the delivery device as much as by the drug. Intrathecal pumps are surgically implanted under the skin of the abdomen and connected to a catheter threaded into the spinal fluid. They deliver tiny, precisely metered doses of medication directly to the spinal cord. The growing number of patients with these implanted devices means that more people are showing up for unrelated surgeries and procedures while carrying an active drug pump, and there is surprisingly little consolidated guidance on how to manage them during those encounters.³¹ Patients need to coordinate with multiple specialists, watch for catheter-related complications, and attend regular refill appointments. It is effective therapy for some people with truly severe, otherwise-untreatable pain, but it is a commitment that shapes daily life in ways a pill never would.

This reality is exactly what motivates the push toward oral and injectable peptide formulations. If cyclization, CPP shuttles, and other engineering strategies can eventually produce peptide painkillers that survive the gut and reach their targets without a pump, the patient experience would change dramatically. For now, though, the gap between laboratory promise and bedside convenience remains the field’s defining challenge.